Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP942 | DOI: 10.1530/endoabs.81.EP942

Hôpital Cheikh Zayd, Endocrinology, Rabat, Morocco


Introduction: Mayer-Rokitansky-Küster-Hauser syndrome (MRKH) is a rare malformation of the birth canal in women. It is defined as agenesis of the uterus and vagina with normal development of secondary sexual characteristics and a normal karyotype (46, XX). This is an entity with a heavy psychological impact requiring multidisciplinary care.

Observation 1: We report the case of a 16-year-old patient with a history of delayed puberty in the sister, who consulted for primary amenorrhea. Clinical examination revealed a height delay of -3 standard deviation, a weight delay of -1 standard deviation and a Tanner stage A1 S1 P1. Hormonal exploration found hypergonadotropic hypogonadism. The karyotype showed a female genetic sex (46 XX). Abdominal pelvic ultrasound and MRI revealed utero-vaginal aplasia. The impact assessment showed a bone age of 13 years compared to a chronological age of 16 years. Hormone therapy treatment is started, associated with psychological care.

Observation 2: A 15-year-old patient with no notable history consulted for delayed height and puberty. Clinical examination revealed a statural delay at -2 standard deviation and Tanner stage S1P1A1. Hormonal workup showed hypergonadotropic hypogonadism with FSH at 133.4 IU/l and LH at 28.85 IU/l with low plasma estradiol levels. The karyotype showed a female genetic sex of 46, XX in the absence of Y chromosomal material. Ultrasound and abdominal pelvic MRI revealed utero-vaginal hypoplasia. The impact assessment showed a bone age of 12 years compared to a chronological age of 15 years. The diagnosis of MRKH was made with the absence of associated malformations. Estrogen therapy was started in our patient.

Discussion and conclusion: MRKH syndrome is a rare congenital malformation characterized by hypergonadotropic hypogonadism and which should be considered in the presence of any utero-vaginal abnormality. MRI is the exam of choice for the diagnosis of this syndrome. Its management is multidisciplinary and is essentially based on hormone replacement therapy.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts